Risk of Gastrointestinal Bleeding Associated with <i>Helicobacter pylori</i> Infection in Patients with Hemophilia or von Willebrand’s Syndrome

Braden, Barbara; Wenke, A.; Karich, Hans‐Joachim; Dietrich, Christoph F.; Scharrer, I.; Caspary, W. F.; Lembcke, B.

doi:10.1046/j.1523-5378.1998.08052.x

Cited by 16 publications

(20 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our group of haemophilic patients with upper gastrointestinal bleeding, H. pylori infection was diagnosed in 71.7%, whereas in patients with no bleeding history, the infection was found in 39.0% of the subjects. Similar results were reported by Braden et al who found 71% of H. pylori-positive patients with gastrointestinal bleeding, and 25% of H. pyloripositive patients with no history of bleeding episodes [19]. Upper gastrointestinal bleeding was statistically more frequent in H. pylori-positive patients with haemophilia than in the H. pylori-negative haemophilic patients (71.7% vs. 28.3%; P < 0.0002).…”

Section: Discussionsupporting

confidence: 88%

“…As shown by comparative studies, the prevalence of H. pylori infection in the haemophilia population does not differ from the prevalence rate of infection with this bacterium in the general population [19,21]. However, the prevalence rate of upper gastrointestinal bleeding is statistically more significant in haemophilic patients than in those with no congenital coagulopathies [13,19,21]. The bleeding may result from small mucosal injuries because of the H. pylori pathogenic factors which do not manifest themselves clinically in patients with normal haemostasis.…”

Section: Discussionmentioning

confidence: 99%

“…Similar results were reported by Braden et al who found 71% of H. pylori ‐positive patients with gastrointestinal bleeding, and 25% of H . pylori ‐positive patients with no history of bleeding episodes [19]. Upper gastrointestinal bleeding was statistically more frequent in H. pylori ‐positive patients with haemophilia than in the H. pylori ‐negative haemophilic patients (71.7% vs. 28.3%; P < 0.0002).…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Helicobacter pylori infection in patients with haemophilia in Poland: prevalence and risk of upper gastrointestinal bleeding

Szczepanik¹,

Zaleska²,

Wiszniewski³

et al. 2005

Haemophilia

View full text Add to dashboard Cite

Infection with Helicobacter pylori is the main aetiological factor for erosive gastritis and duodenal or gastric peptic ulcers often complicated with life-threatening bleeding in patients with coagulation disorders. The aim of this prospective study was to evaluate the prevalence of Helicobacter pylori infection in haemophilia patients, and to assess the risk of gastrointestinal bleeding associated with this infection. From 2000 to 2002, 146 patients with haemophilia (129, haemophilia A; 13, haemophilia B), mean age, 39.9 years (+/-7.3), were investigated for H. pylori infection using IgG and IgA latex serological test. The control group included 100 men with no coagulation disorders, mean age, 40.9 years (+/-9.2). For 72 (49.3%) patients with haemophilia and 39 controls (39.0%) serological tests were positive indicating the presence of H. pylori infection (P =0.1112). A history of gastrointestinal bleeding was reported in 46 patients (31.5%) with haemophilia and in two control group patients (2.0%) (P < 0.0001). Gastrointestinal bleeding was significantly more frequent in patients with haemophilia infected with H. pylori (33/46; 71.7%) than in patients with no H. pylori infection (13/46; 28.3%; P = 0.0002). In conclusion, the prevalence of H. pylori infection in haemophilic patients in Poland is comparable with that in patients with no coagulation disorders. Helicobacter pylori infection is a risk factor for duodenal and gastric ulcer bleeding in haemophilia patients. In view of the high frequency of upper gastrointestinal bleeding associated with H. pylori infection, we believe that screening and eradication therapy are appropriate in haemophilia patients.

show abstract

Section: Discussionsupporting

confidence: 88%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Helicobacter pylori infection in patients with haemophilia in Poland: prevalence and risk of upper gastrointestinal bleeding

Szczepanik¹,

Zaleska²,

Wiszniewski³

et al. 2005

Haemophilia

View full text Add to dashboard Cite

show abstract

“…Of PWH, 10-25% experience episodes, of GI bleeding [6,11,12,[23][24][25][26] and recurrent bleeding is common. The widespread usage of clotting factor concentrates, H2 blockers and proton pump inhibitors have drastically reduced the high mortality reported in early studies when gastrointestinal haemorrhage was the most frequent cause of death [11].…”

Section: Discussionmentioning

confidence: 99%

Upper gastrointestinal bleeding in haemophiliacs: incidence and relation to use of non‐steroidal anti‐inflammatory drugs

et al. 2007

View full text Add to dashboard Cite

This multicentre study sought to estimate the incidence of upper gastrointestinal (UGI) bleeding in haemophiliacs and its relationship to use of non-steroidal anti-inflammatory drugs (NSAIDs). Cox models were used to estimate relative hazards (RH) with 95% confidence intervals (CI) for postulated risk factors. Conditional logistic regression and stored sera were used to assess UGI bleeding risk with Heliobacter pylori seropositivity in cases compared with closely matched controls. During a mean of 17.4 months (range 2-34), 2285 participants, ages 13-89 (mean 36.5) were followed for 3309 person-years (py). Forty-two experienced a UGI bleeding event (incidence 1.3 per 100 py), most from ulcer (11), gastritis (four), varices (five) and Mallory Weiss tears (eight). RH was significantly increased with traditional NSAID use for <1 month (OR: 3.66; 95% CI: 1.1-11.9), but not with coxibs use. RH was significantly and independently increased with age >46 years (3.5; 95% CI: 1.1-10.6) and hepatic decompensation (4.4; 95% CI: 1.7-11.6). Likelihood of bleeding was substantially but not significantly increased (OR: 4.6; 95% CI: 0.3-83.9) with H. pylori seropositivity. These findings suggest that coxibs are a safer alternative than traditional NSAIDs in the treatment of haemophilic arthropathy.

show abstract

“…These procedures are cost efficient for the health system, if one takes into account that the screening, followed by treatment of all infected patients, yields a reduction of direct costs over a 5-year period of 130 US$ per screened patient [265]. Therefore, due to increased bleeding complications, H. pylori screening and therapy appear mandatory in patients with bleeding disorders [266]. This conduct would also be applicable for patients undergoing prophylactic anticoagulation therapy [267] like aspirin [95].…”

Section: Other Hematologic Manifestationsmentioning

confidence: 99%

Helicobacter pylori and Hematologic Diseases

Campuzano-Maya¹

2016

Extradigestive Manifestations of Helicobacter Pylori Infection - An Overview

View full text Add to dashboard Cite

Helicobacter pylori infection is the most common infection of the human species, with developing countries displaying a marked disadvantage in contrast to developing countries. While H. pylori infection is asymptomatic in most infected individuals, it is intimately related to malignant diseases of the stomach, such as gastric cancer and gastric MALT lymphoma, as well as benign diseases, for example chronic gastritis and duodenal and gastric peptic ulcers. Since the discovery that gastric mucosa could be colonized by bacteria, evidence of greater than 50 extragastric manifestations has been reported, linking H. pylori infection and the development of diseases associated with cardiology, dermatology, endocrinology, obstetrics and gynecology, hematology, pneumology, neurology, odontology, ophthalmology, otorhinolaryngology, and pediatrics. This chapter presents the extragastric manifestations of H. pylori infection expressed through hematologic diseases; particularly those included in the international consensus, and discusses guidelines for the management of H. pylori infection, such as iron deficiency, vitamin B 12 (cobalamin) deficiency, and immune thrombocytopenia. Other manifestations reviewed include immune neutropenia, antiphospholipid syndrome, and plasma cell dyscrasias, such us monoclonal gammopathy of undetermined significance, multiple myeloma, and Henoch-Schönlein purpura.

show abstract

Risk of Gastrointestinal Bleeding Associated with Helicobacter pylori Infection in Patients with Hemophilia or von Willebrand’s Syndrome

Abstract: The rate of H. pylori infection and dyspepsia in patients with bleeding disorders is similar to the prevalence in the normal population. Due to increased bleeding complications, H. pylori screening and therapy appears mandatory in patients with bleeding disorders.

Cited by 16 publications

References 13 publications

Helicobacter pylori infection in patients with haemophilia in Poland: prevalence and risk of upper gastrointestinal bleeding

Helicobacter pylori infection in patients with haemophilia in Poland: prevalence and risk of upper gastrointestinal bleeding

Upper gastrointestinal bleeding in haemophiliacs: incidence and relation to use of non‐steroidal anti‐inflammatory drugs

Helicobacter pylori and Hematologic Diseases

Contact Info

Product

Resources

About